The estimated Net Worth of Elizabeth A Grammer is at least $6.69 Million dollars as of 20 August 2024. Ms. Grammer owns over 7,089 units of Ardelyx Inc stock worth over $1,146,585 and over the last 10 years she sold ARDX stock worth over $4,749,859. In addition, she makes $791,408 as Chief Legal and Administrative Officer at Ardelyx Inc.
Elizabeth has made over 38 trades of the Ardelyx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she sold 7,089 units of ARDX stock worth $41,542 on 20 August 2024.
The largest trade she's ever made was selling 284,170 units of Ardelyx Inc stock on 6 May 2024 worth over $2,523,430. On average, Elizabeth trades about 14,077 units every 67 days since 2015. As of 20 August 2024 she still owns at least 192,380 units of Ardelyx Inc stock.
You can see the complete history of Ms. Grammer stock trades at the bottom of the page.
Elizabeth Grammer Esq. serves as Chief Legal and Administrative Officer of the Company. She has served as our General Counsel since May 2014 and formerly served as our vice president responsible for legal affairs from December 2012 until May 2014. From 2006 to December 2012, Ms. Grammer served as an independent outside corporate counsel for public and private biotechnology companies, including Ardelyx from January 2010 until December 2012. From 2001 to 2006, Ms. Grammer served as Vice President and General Counsel of Trine Pharmaceuticals, Inc., a biopharmaceutical company. In addition, Ms. Grammer previously served as independent outside corporate counsel to GelTex Pharmaceuticals, a biopharmaceutical company. Ms. Grammer received a B.A. from Boston University and a J.D. from Stanford Law School.
As the Chief Legal and Administrative Officer of Ardelyx Inc, the total compensation of Elizabeth Grammer at Ardelyx Inc is $791,408. There are 3 executives at Ardelyx Inc getting paid more, with Michael Raab having the highest compensation of $1,728,920.
Elizabeth Grammer is 56, she's been the Chief Legal and Administrative Officer of Ardelyx Inc since 2020. There are 9 older and 8 younger executives at Ardelyx Inc. The oldest executive at Ardelyx Inc is Gordon Ringold, 69, who is the Independent Director.
Elizabeth's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: